- Home
- VLO vs REGN Comparison
VLO vs REGN Comparison
Compare VLO & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLO
- REGN
- Stock Information
- Founded
- VLO 1980
- REGN 1988
- Country
- VLO United States
- REGN United States
- Employees
- VLO N/A
- REGN N/A
- Industry
- VLO Integrated oil Companies
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- VLO Energy
- REGN Health Care
- Exchange
- VLO Nasdaq
- REGN Nasdaq
- Market Cap
- VLO 50.4B
- REGN 59.5B
- IPO Year
- VLO N/A
- REGN 1991
- Fundamental
- Price
- VLO $170.66
- REGN $652.91
- Analyst Decision
- VLO Buy
- REGN Buy
- Analyst Count
- VLO 18
- REGN 21
- Target Price
- VLO $176.71
- REGN $779.00
- AVG Volume (30 Days)
- VLO 2.4M
- REGN 1.1M
- Earning Date
- VLO 10-23-2025
- REGN 10-28-2025
- Dividend Yield
- VLO 2.67%
- REGN 0.54%
- EPS Growth
- VLO N/A
- REGN 2.88
- EPS
- VLO 4.78
- REGN 41.59
- Revenue
- VLO $116,553,000,000.00
- REGN $14,247,800,000.00
- Revenue This Year
- VLO N/A
- REGN N/A
- Revenue Next Year
- VLO N/A
- REGN $5.02
- P/E Ratio
- VLO $35.74
- REGN $15.70
- Revenue Growth
- VLO N/A
- REGN 2.89
- 52 Week Low
- VLO $99.00
- REGN $476.49
- 52 Week High
- VLO $178.43
- REGN $935.86
- Technical
- Relative Strength Index (RSI)
- VLO 59.19
- REGN 73.72
- Support Level
- VLO $156.26
- REGN $576.00
- Resistance Level
- VLO $176.22
- REGN $588.71
- Average True Range (ATR)
- VLO 4.96
- REGN 17.70
- MACD
- VLO 0.77
- REGN 7.89
- Stochastic Oscillator
- VLO 73.45
- REGN 94.06
About VLO Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).